Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 420 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016, provides an overview of the Recurrent Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Recurrent glioblastoma multiforme (GBM) is one of the most aggressive primary brain tumors. Recurrent tumors develop near the original site or at more distant satellite lesions within the brain. Symptoms include headache, nausea, vomiting, vision problem, seizures and intracranial hemorrhage. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Recurrent Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 46, 11 and 7 respectively for Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 5 molecules, respectively for Recurrent Glioblastoma Multiforme (GBM).

Recurrent Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Recurrent Glioblastoma Multiforme (GBM) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Recurrent Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Recurrent Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Recurrent Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Recurrent Glioblastoma Multiforme (GBM) (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Recurrent Glioblastoma Multiforme (GBM) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Recurrent Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 6
Recurrent Glioblastoma Multiforme (GBM) Overview 7
Therapeutics Development 8
Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies 10
Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes 13
Recurrent Glioblastoma Multiforme (GBM) - Pipeline Products Glance 14
Recurrent Glioblastoma Multiforme (GBM) - Products under Development by Companies 17
Recurrent Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes 21
Recurrent Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 22
Recurrent Glioblastoma Multiforme (GBM) - Therapeutics Assessment 65
Drug Profiles 79
Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects 398
Recurrent Glioblastoma Multiforme (GBM) - Discontinued Products 400
Recurrent Glioblastoma Multiforme (GBM) - Product Development Milestones 401
Appendix 411

List of Tables

Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H2 2016 16
Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2016 17
Number of Products under Development by Companies, H2 2016 18
Number of Products under Development by Companies, H2 2016 (Contd..1) 19
Number of Products under Development by Companies, H2 2016 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2016 21
Comparative Analysis by Late Stage Development, H2 2016 22
Comparative Analysis by Clinical Stage Development, H2 2016 23
Comparative Analysis by Early Stage Development, H2 2016 24
Products under Development by Companies, H2 2016 25
Products under Development by Companies, H2 2016 (Contd..1) 26
Products under Development by Companies, H2 2016 (Contd..2) 27
Products under Development by Companies, H2 2016 (Contd..3) 28
Products under Investigation by Universities/Institutes, H2 2016 29
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H2 2016 30
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Agenus, Inc., H2 2016 31
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc., H2 2016 32
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc., H2 2016 33
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H2 2016 34
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Arog Pharmaceuticals, Inc., H2 2016 35
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Axelar AB, H2 2016 36
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by BeiGene, Ltd., H2 2016 37
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 38
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical, Inc., H2 2016 39
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Bristol-Myers Squibb Company, H2 2016 40
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Cantex Pharmaceuticals, Inc., H2 2016 41
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H2 2016 42
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Coherus BioSciences, Inc., H2 2016 43
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Cortice Biosciences, Inc., H2 2016 44
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co., Ltd., H2 2016 45
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H2 2016 46
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H2 2016 47
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H2 2016 48
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Genzyme Corporation, H2 2016 49
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline Plc, H2 2016 50
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H2 2016 51
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2016 52
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Inspyr Therapeutics Inc, H2 2016 53
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Kadmon Corporation, LLC, H2 2016 54
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 55
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H2 2016 56
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics, Inc., H2 2016 57
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co., Inc., H2 2016 58
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Neonc Technologies Inc, H2 2016 59
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H2 2016 60
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 61
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co. KG, H2 2016 62
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc., H2 2016 63
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by StemGen S.p.A, H2 2016 64
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics, Inc., H2 2016 65
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2016 66
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc., H2 2016 67
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 68
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories, Inc., H2 2016 69
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd., H2 2016 70
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Vaximm AG, H2 2016 71
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Virttu Biologics Limited, H2 2016 72
Assessment by Monotherapy Products, H2 2016 73
Assessment by Combination Products, H2 2016 74
Number of Products by Stage and Target, H2 2016 76
Number of Products by Stage and Mechanism of Action, H2 2016 80
Number of Products by Stage and Route of Administration, H2 2016 84
Number of Products by Stage and Molecule Type, H2 2016 86
Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2016 406
Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..1), H2 2016 407
Recurrent Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2016 408